Director/PDMR Shareholding

16th March 2023

Medcaw Investments Plc - 13078596
(“Medcaw Investments” or the “Company”)

Directors Dealing

Medcaw Investments Plc (LSE:MCI), a special purpose acquisition vehicle, announces that it has received notification that Marcus Yeoman, Non-executive Director, has acquired a total of 95,908 shares in the Company in the following transactions.

Date Shares acquired Price per share
14 March 2023 25,000 2.95p
16 March 2023 35,816 3.49p
16 March 2023 25,062 3.99p
16 March 2023 10,030 4.985p

Following the transactions, Marcus Yeoman is interested in 126,808 shares representing  0.74% of the Company’s issued share capital.

This announcement contains inside information for the purposes of UK Market Abuse Regulation.  The persons who arranged the release of this information are the Directors of the Company.

*** ENDS ***

Enquiries:

Medcaw Investments Plc  +44 (0)203 918 8797

Sarah Cope, Executive Chairperson

Zeus Capital Limited  +44 (0) 203 829 5000

Alexandra Campbell-Harris

1 Details of the person discharging managerial responsibilities
a) Name Marcus Yeoman
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification/amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Medcaw Investments plc
b) LEI 213800UTM4MRTZHJ8C21
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Identification code
Ordinary shares of 1 pence each


GB00BM8SQP62 
b) Nature of the transaction Acquisition
c) Price(s) and volume(s)
Price(s) Volume(s)
2.95p 25,000
3.49p
3.99p
4.985p
35,816
25,062
10,030
d) Aggregated information
-  Aggregated volume
 -  Price

95,908
£3,487.45
e) Date of the transaction 14th to 16th March 2023
f) Place of the transaction AIM
UK 100

Latest directors dealings